News

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent panel that makes vaccine recommendations to the Centers for Disease Control and ...
Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent ...
That whole meeting was a travesty,” says Fiona Havers, a physician and epidemiologist. After the ACIP firings, Havers ...
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Zacks Investment Research on MSN8d
Moderna Stock Gains on Encouraging Flu Vaccine Data
Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...
The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.
The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...